Related Experiment Video
Updated: Aug 6, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats
1Department of Basic Science, Astellas Research Institute of America, Evanston, Illinois 60201, USA.
Abstract:
We measured the expression levels of transforming growth factor-beta (TGF-beta) and vascular cell adhesion molecule (VCAM-1) in rat kidney grafts undergoing chronic rejection and treated the rats with six different regimens in order to determine correlation between their expression levels and severity of chronic rejection. F344 or Lewis kidneys were transplanted into Lewis recipients to generate allograft or isograft groups, respectively. Graft recipients were treated with one of the following regimens: (1) untreated isograft, (2) untreated allograft, (3) tacrolimus (FK506), 1 mg/kg/d for 10 days, (4) triptolide (PG490-88), 0.5 mg/kg/d for 10 days, and (5) leflunomide analogue (FK778), 10 mg/kg/d for 10 days. Kidneys were harvested on day 90 after transplantation and subjected to histological analysis and gene expression analysis by real-time reverse transcriptase polymerase chain reaction (RT-PCR) for TGF-beta and VCAM-1. Gene expression values were compared to measurements of chronic rejection by linear regression analysis. Modified Banff score for transplant pathology show that chronic rejection was mild in the FK778 group, moderate in the PG490-88 group, and severe in the FK506 and allograft control groups. Overall, the expression levels of TGF-beta and VCAM-1 show high correlations with histological changes of chronic rejection. Suppression of the expression levels of TGF-beta and VCAM-1 is associated with the amelioration of chronic rejection by various drugs, suggesting that these molecules are important key molecules in chronic rejection.
Insights
Transforming growth factor-beta (TGF-beta) and vascular cell adhesion molecule (VCAM-1) levels correlate with chronic kidney rejection severity. Suppressing these molecules may ameliorate rejection, indicating their key role in transplant pathology.
Area of Science:
- Transplantation immunology
- Molecular biology
- Renal pathology
Background:
- Chronic rejection remains a significant challenge in organ transplantation.
- Identifying molecular markers associated with chronic rejection is crucial for therapeutic development.
Purpose of the Study:
- To investigate the correlation between transforming growth factor-beta (TGF-beta) and vascular cell adhesion molecule (VCAM-1) expression levels and the severity of chronic kidney allograft rejection.
- To assess the impact of different immunosuppressive regimens on these molecular markers and rejection severity.
Main Methods:
- Rat kidney allograft and isograft models were established.
- Grafts were treated with various regimens including tacrolimus (FK506), triptolide (PG490-88), and a leflunomide analogue (FK778).
- Gene expression of TGF-beta and VCAM-1 was quantified using RT-PCR, and histological analysis was performed using the Modified Banff score.
Main Results:
- Chronic rejection severity varied across treatment groups, being mild with FK778, moderate with PG490-88, and severe with FK506 and untreated allografts.
- Expression levels of TGF-beta and VCAM-1 showed a strong positive correlation with the histological severity of chronic rejection.
- Drug-induced suppression of TGF-beta and VCAM-1 expression was associated with reduced chronic rejection.
Conclusions:
- TGF-beta and VCAM-1 are key molecular players in the pathogenesis of chronic kidney allograft rejection.
- Monitoring and targeting TGF-beta and VCAM-1 expression may offer therapeutic strategies to mitigate chronic rejection.
More Related Videos
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
TGF - β Signaling Pathway

